Biochemical assays for the discovery of TDP1 inhibitors

Drug screening against novel targets is warranted to generate biochemical probes and new therapeutic drug leads. TDP1 and TDP2 are two DNA repair enzymes that have yet to be successfully targeted. TDP1 repairs topoisomerase I-, alkylation-, and chain terminator-induced DNA damage, whereas TDP2 repai...

Full description

Saved in:
Bibliographic Details
Published in:Molecular cancer therapeutics 2014-08, Vol.13 (8), p.2116-2126
Main Authors: Marchand, Christophe, Huang, Shar-yin N, Dexheimer, Thomas S, Lea, Wendy A, Mott, Bryan T, Chergui, Adel, Naumova, Alena, Stephen, Andrew G, Rosenthal, Andrew S, Rai, Ganesha, Murai, Junko, Gao, Rui, Maloney, David J, Jadhav, Ajit, Jorgensen, William L, Simeonov, Anton, Pommier, Yves
Format: Article
Language:English
Subjects:
Animals
Antineoplastic Agents - chemistry
Antineoplastic Agents - pharmacology
Camptothecin - pharmacology
Cell Line
Cell Survival - drug effects
Chickens
Drug Screening Assays, Antitumor - methods
Drug Synergism
Humans
Peptide Fragments - chemistry
Phosphodiesterase Inhibitors - chemistry
Phosphodiesterase Inhibitors - pharmacology
Phosphoric Diester Hydrolases - chemistry
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Drug screening against novel targets is warranted to generate biochemical probes and new therapeutic drug leads. TDP1 and TDP2 are two DNA repair enzymes that have yet to be successfully targeted. TDP1 repairs topoisomerase I-, alkylation-, and chain terminator-induced DNA damage, whereas TDP2 repairs topoisomerase II-induced DNA damage. Here, we report the quantitative high-throughput screening (qHTS) of the NIH Molecular Libraries Small Molecule Repository using recombinant human TDP1. We also developed a secondary screening method using a multiple loading gel-based assay where recombinant TDP1 is replaced by whole cell extract (WCE) from genetically engineered DT40 cells. While developing this assay, we determined the importance of buffer conditions for testing TDP1, and most notably the possible interference of phosphate-based buffers. The high specificity of endogenous TDP1 in WCE allowed the evaluation of a large number of hits with up to 600 samples analyzed per gel via multiple loadings. The increased stringency of the WCE assay eliminated a large fraction of the initial hits collected from the qHTS. Finally, inclusion of a TDP2 counter-screening assay allowed the identification of two novel series of selective TDP1 inhibitors.
ISSN:1535-7163
1538-8514
DOI:10.1158/1535-7163.mct-13-0952